AZN vs COO: fair value comparison
AstraZeneca PLC and The Cooper Companies, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. COO carries the stronger quality grade.
| AZN | COO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $162.47 | $53.91 |
| 12-month range | $156.93–$202.39 | $60.19–$83.92 |
| Sector rank | #5 of 113 Healthcare | #7 of 113 Healthcare |
| Quality grade | C | B |
| Leverage | Moderate | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Downtrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AZN fair value analysis · COO fair value analysis